Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given an average recommendation of “Hold” by the eight ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $4.9250.

A number of brokerages recently issued reports on IRWD. Citizens Jmp raised their target price on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Jefferies Financial Group restated a “hold” rating and issued a $3.70 price objective on shares of Ironwood Pharmaceuticals in a research note on Thursday. Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. Finally, Wells Fargo & Company increased their price target on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a report on Monday, January 5th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IRWD. Bank of America Corp DE lifted its position in Ironwood Pharmaceuticals by 248.3% during the third quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock valued at $15,321,000 after purchasing an additional 8,337,672 shares during the period. Millennium Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after buying an additional 4,140,439 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 147.6% in the 2nd quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company’s stock valued at $4,685,000 after buying an additional 3,904,498 shares during the period. AQR Capital Management LLC boosted its stake in shares of Ironwood Pharmaceuticals by 144.3% in the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after buying an additional 3,641,762 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in Ironwood Pharmaceuticals by 616.3% during the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after acquiring an additional 3,436,036 shares during the period.

Ironwood Pharmaceuticals Stock Down 6.6%

IRWD stock opened at $3.42 on Monday. The stock has a market capitalization of $556.37 million, a PE ratio of 26.31 and a beta of 0.24. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $5.78. The firm has a 50 day moving average of $4.28 and a 200 day moving average of $2.84.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). The company had revenue of $47.71 million for the quarter, compared to analyst estimates of $86.10 million. Ironwood Pharmaceuticals had a net margin of 8.11% and a negative return on equity of 13.72%. On average, equities research analysts expect that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

More Ironwood Pharmaceuticals News

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Analyst price-target lift from Citizens JMP — Citizens JMP raised its price target to $10 and kept a “market outperform” rating, signaling significant upside potential if execution or pipeline news turns favorable. Read More.
• Neutral Sentiment: Q4 earnings call highlighted continued strength in LINZESS sales even as overall revenue fell; investors will watch whether LINZESS can stabilize top-line trends going forward. Read More.
• Neutral Sentiment: Post-quarter valuation and 2026 revenue guidance analysis is prompting re‑rating discussions — analysts and commentators are reworking models after the miss, which could amplify volatility while estimates are adjusted. Read More.
• Neutral Sentiment: Market commentaries explaining the share drop (e.g., coverage pieces) are framing the move as a reaction to the earnings miss plus guidance/pipeline uncertainty rather than a single catalyst. Read More.
• Negative Sentiment: Pipeline setback for apraglutide and an extended development timeline — Seeking Alpha and other analysts lowered expectations after management pushed timelines, increasing risk to future upside from the pipeline. Read More.
• Negative Sentiment: Q4 results missed estimates — IRWD reported a loss for the quarter, with revenue falling ~47% YoY and coming in well below consensus, which directly triggered the share sell-off. Read More.
• Negative Sentiment: Zacks Research downgraded IRWD from “strong-buy” to “hold,” removing a supportive endorsement and adding selling pressure amid the disappointing quarter. Read More.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.